Lux Research launches China BioPharma service

15 February 2012

Market intelligence and technology scouting group Lux Research has announced the launch of its new China BioPharma Intelligence service, extending its coverage to a strategic market that poses both partnering opportunities and competitive threats to established western biopharma companies.

Comprising a team of well-networked, native analysts based in Shanghai, Singapore and Boston, the service will provide Lux Research’s global clients with ongoing technology scouting and market intelligence from one of the world’s fastest-growing biopharmaceutical markets and the world’s most dynamic economy.

30-fold increase in China’s basic research funding

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK